Nov. 24 at 12:51 AM
$AFMD The longer BP waits, the harder the RMAT pushes the value here, as I believe our rep has informed the court we're on the cusp of Acimtamig approval and a marketable drug.. or advance of
$NPV via acceleration of the timeline:
$225 >>
$450 >>
$900M value.
"The combination is being evaluated in the on-going LuminICE-203 multicenter, multi-cohort phase 2 trial."